Exelixis, Inc. (EXEL) Stock
Valuation
Financials & Margins
Annual Financials (USD)
Balance Sheet (USD)
Latest News
Cash Flow (USD)
Valuation & Return Ratios
Peer Comparison
About Exelixis, Inc.
Exelixis, Inc. is led by CEO Michael Morrissey, employs 1,077 people, headquartered in Alameda, US, publicly traded since 2000.
Exelixis, Inc. (EXEL) stock trades at $62.23 with a market capitalization of $15.64B. The stock is valued at a price-to-earnings (P/E) ratio of 17.78, price-to-book of 7.96, price-to-sales of 6.04. Over the past 52 weeks the stock has ranged between $33.76 and $62.96, and currently trades 1.2% below its 52-week high.
On profitability, Exelixis, Inc. generates a return on equity (ROE) of 42.49%, above the typical market range of roughly 12-15%, return on capital employed of 45.56%, an operating margin of 39.43%, a net profit margin of 35.33%.
In its most recent fiscal year, Exelixis, Inc. reported annual revenue of $2.3B, net profit of $783.0M. Over the last 5 fiscal years, revenue grew at an average annual rate of 18.6%, and net profit grew at an average annual rate of 47.5%. Over that span net profit grew faster than revenue, so net margin widened.
The balance sheet shows a debt-to-equity ratio of 0.09 (debt below half of shareholders' equity), a current ratio of 3.55, total assets of $2.8B, $482.0M in cash and equivalents.
EXEL has an average daily trading volume of 2,474,193 shares, a beta of 0.42 (historically less volatile than the overall market).
Related Healthcare Stocks
Popular Stocks
Related stock screens
Data for information only, not investment advice. Figures may be delayed or inaccurate; verify against company filings. See our disclaimer.